Benjamin Edwards Inc’s Recursion Pharmaceuticals RXRX Stock Holding History

Benjamin Edwards Inc’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$618K	Buy	168,540 +23,888	+17%	+$79.5K	0.01%	978
2026 Q1	$444K	Sell	144,652 -2,137	-1%	-$8.26K	﹤0.01%	1041
2025 Q4	$600K	Buy	146,789 +3,625	+3%	+$18K	0.01%	891
2025 Q3	$699K	Sell	143,164 -21,612	-13%	-$113K	0.01%	813
2025 Q2	$834K	Sell	164,776 -6,051	-4%	-$29.7K	0.01%	691
2025 Q1	$904K	Buy	170,827 +11,833	+7%	+$86.3K	0.01%	607
2024 Q4	$1.07M	Sell	158,994 -3,487	-2%	-$23.4K	0.02%	587
2024 Q3	$1.07M	Buy	162,481 +161,259	+13,196%	+$1.16M	0.02%	582
2024 Q2	$9K	Sell	1,222 -465	-28%	-$4.06K	﹤0.01%	626
2024 Q1	$17K	Buy	1,687 +608	+56%	+$6.77K	﹤0.01%	595
2023 Q4	$11K	Buy	+1,079	New	+$7.69K	﹤0.01%	582

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Benjamin Edwards Inc's RXRX Position: Q2 2026 in Review

Benjamin Edwards Inc increased its Recursion Pharmaceuticals (RXRX) stake by 17% in Q2 2026, buying an estimated $79.5K and bringing the position to 168,540 shares worth $618K. The position accounts for 0.01% of the portfolio, ranked #978.

Benjamin Edwards Inc first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.07M in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Benjamin Edwards Inc held 168,540 shares of Recursion Pharmaceuticals worth $618K as of Q2 2026.
Benjamin Edwards Inc bought 23,888 Recursion Pharmaceuticals shares in Q2 2026, an estimated $79.5K.
Recursion Pharmaceuticals made up 0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #978 holding.
Benjamin Edwards Inc first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Benjamin Edwards Inc's Recursion Pharmaceuticals position peaked at $1.07M in Q4 2024.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.